Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

has spurred a 3.2% rise in the company's stock on Wednesday. The drug, originally... ByInvesting.com • Nov 09, 2023 Eli Lilly is still seeking UK approval on pen for weight-loss drug By Maggie ...

After years of preparation, Eli Lilly is ... data from the pen, and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom ...